Cover Image
市場調查報告書

OTC (Over-the-Counter) 醫藥品的全球市場 (2016∼2020年)

Global Over-the-Counter Drug Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 366876
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
OTC (Over-the-Counter) 醫藥品的全球市場 (2016∼2020年) Global Over-the-Counter Drug Market 2016-2020
出版日期: 2016年08月12日 內容資訊: 英文 120 Pages
簡介

所謂成藥 (一般醫藥品) ,是沒有醫生處方箋便能購買的醫藥品。在美國的情況,成藥自FDA (美國食品藥物管理局)取得了「即使沒有醫生的認證也能安全使用」的認證之後,使用在不用找醫生診治的疾病(頭痛,搔癢,咳嗽、感冒,失眠症,戒煙,減重,腸胃不順,蛀牙等)的治療。成藥在醫院、藥局、雜貨店、目錄銷售、網路商店等各種流通管道銷售。全球成藥的市場,預計2016∼2020年以6.19%的年複合成長率成長。

本報告提供全球OTC (Over-the-Counter) 醫藥品的市場相關分析,成藥定義和概要,市場概要和結構,市場規模趨勢 (今後5年的預測值),各產品領域 (治療項目) 及各地區詳細趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 成藥概要

  • 成藥的認證:規定上的過程
  • FDA (美國食品藥物管理局) 的成藥認證流程
  • 新興國家市場上成藥的普及策略

第6章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第7章 各治療項目的市場區隔

第8章 全球呼吸系統的成藥市場

  • 市場概要

第9章 全球營養補充品市場

  • 市場概要

第10章 全球OTC腸胃藥市場

  • 市場概要
  • 各治療項目的市場區隔

第11章 全球OTC止痛藥市場

  • 市場概要
  • 各治療項目的市場區隔

第12章 各給藥途徑的市場區隔

  • 口服藥
  • 塗劑 (外用製劑)
  • 非口服藥

第13章 地區區分

  • 全球成藥市場:各地區的詳細趨勢 (今後5年份)
  • 南北美洲市場
  • 美國市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 德國市場
  • 法國市場
  • 亞太地區市場
  • 中國市場
  • 日本市場
  • 印度市場

第14章 推動市場要素

  • 從處方藥轉換到OTC
  • 緩慢的管理體制與流通管道
  • 有成本效率的成藥
  • 自我治療的普及

第15章 推動因素的影響力

第16章 市場課題

  • 假藥
  • 有效的文件不足
  • 大金額的廣告費用

第17章 推動因素、課題的影響力

第18章 市場趨勢

  • 線上資源的利用擴大
  • 推銷/行銷活動
  • 策略性聯盟

第19章 供應商環境

  • 競爭方案

第20章 主要供應商分析

  • GSK
  • Johnson & Johnson
  • Pfizer
  • Bayer HealthCare
  • Sanofi
  • 其他卓越供應商

第21章 附錄

  • 簡稱集

第22章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR10079

About OTC Drugs

OTC drugs are medicines that can be bought without a prescription from a doctor because the US FDA considers them safe for use without medical supervision. These drugs are used to treat conditions that do not necessarily require a doctor's advice, such as pain, itches, cough and cold, sleeping problems, smoking cessation, weight problems, gastrointestinal problems, and tooth decay. They are sold through hospitals, pharmaceutical stores, grocery stores, catalogs, and online retail stores.

Technavio's analysts forecast the global over-the-counter (OTC) drug market to grow at a CAGR of 6.19% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global over-the-counter (OTC) drug market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of OTC drugs used to treat disorders, including gastrointestinal disorders, pain, and dermatological and respiratory disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Over-The-Counter (OTC) Drug Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bayer HealthCare
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • Achelios Therapeutics
  • American Health
  • Amgen
  • Arena Pharmaceuticals
  • AstraZeneca
  • BioGaia
  • Bristol Myers Squibb
  • Bukwang Pharmaceutica
  • Chr. Hansen
  • Cipla
  • CoLucid
  • Daiichi Sankyo
  • Dr. Reddy's Laboratories
  • DSM
  • Eisai
  • Eli Lilly
  • EMS
  • Euradite
  • Friggs
  • Genomma Lab Internacional
  • Glanbia
  • Herbalife
  • Himalaya Drug Company
  • Hypermarcas
  • Immune Pharmaceuticals
  • Innovative Med Concepts
  • Mcneil consumer healthcare
  • Mead Johnson
  • Merck
  • Mitsubishi Tanabe Pharma
  • NeurAxon
  • Omega Pharma
  • OptiNose
  • Pain Therapeutics
  • Procter & Gamble
  • Reckitt Benckiser
  • SAVA
  • Sigma Pharmaceuticals
  • Sun Pharma
  • Taisho Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • UCB
  • Unifarma Global Consumer healthcare
  • Valeant Pharmaceuticals
  • Vida Laboratories

Market driver

  • Switching of medications from prescription to OTC
  • For a full, detailed list, view our report

Market challenge

  • Counterfeit drugs
  • For a full, detailed list, view our report

Market trend

  • Accelerated use of online resources
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: OTC drugs: An overview

  • Regulatory pathways for OTC approval
  • FDA OTC drug approval process
  • Strategies to penetrate OTC pharmaceuticals in emerging markets

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by therapeutic class

PART 08: Global respiratory OTC drugs market

  • Market overview

PART 09: Global dietary supplements market

  • Market overview

PART 10: Global gastrointestinal OTC drugs market

  • Market overview
  • Market segmentation by therapeutic class of drug

PART 11: Global OTC pain medications market

  • Market overview
  • Market segmentation by therapeutic class of drug

PART 12: Market segmentation by route of administration

  • Oral
  • Topical
  • Parenteral

PART 13: Geographical segmentation

  • Global OTC drugs market by geography 2015-2020
  • OTC drugs market in Americas
  • OTC drugs market in US
  • OTC drugs market in EMEA
  • OTC drugs market in Germany
  • OTC drugs market in France
  • OTC drugs market in APAC
  • OTC drugs market in China
  • OTC drugs market in Japan
  • OTC drugs market in India

PART 14: Market drivers

  • Switching of medications from prescription to OTC
  • Lenient regulatory framework and distribution channel
  • Cost-effective OTC drugs
  • Rise in self-medication

PART 15: Impact of drivers

PART 16: Market challenges

  • Counterfeit drugs
  • Lack of valid literature
  • High expenditure on advertisements

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Accelerated use of online resources
  • Promotions and marketing initiatives
  • Strategic alliances

PART 19: Vendor landscape

  • Competitive scenario

PART 20: Key vendor analysis

  • GSK
  • Johnson & Johnson
  • Pfizer
  • Bayer HealthCare
  • Sanofi3
  • Other prominent vendors

PART 21: Appendix6

  • List of abbreviations

PART 22: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of OTC drugs market
  • Exhibit 03: Comparison between prescription and OTC drugs
  • Exhibit 04: Advantages and disadvantages of OTC drugs
  • Exhibit 05: Key regulatory bodies for OTC approval
  • Exhibit 06: FDA OTC drug approval process
  • Exhibit 07: Mechanisms to amend OTC drug monograph
  • Exhibit 08: Comparison of OTC NDA and OTC monograph process
  • Exhibit 09: Strategies to establish OTC pharmaceuticals in emerging markets
  • Exhibit 10: Strategies to establish OTC pharmaceuticals in established markets
  • Exhibit 11: Global OTC drugs market 2015-2020 ($ billions)
  • Exhibit 12: Few prescription to OTC switches before the expiry of patents
  • Exhibit 13: Growth potential of various therapy areas in OTC market
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Segmentation of global OTC pharmaceuticals by therapeutic class
  • Exhibit 16: Segmentation of global OTC pharmaceuticals market by therapeutic class 2015
  • Exhibit 17: Global OTC market segmentation: Growth cycle analysis
  • Exhibit 18: List of drugs that underwent Rx-to-OTC switch
  • Exhibit 19: OTC medications for upper respiratory infections
  • Exhibit 20: Global respiratory OTC drugs market 2015-2020 ($ billions)
  • Exhibit 21: Recommendation of dietary supplements by health professionals
  • Exhibit 22: Global dietary supplements market 2015-2020 ($ billions)
  • Exhibit 23: Drugs underwent Rx-to-OTC switch in US
  • Exhibit 24: Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
  • Exhibit 25: Global OTC pain medications market 2015-2020 ($ billions)
  • Exhibit 26: Global OTC analgesics market by therapeutic class of drug 2015
  • Exhibit 27: Segmentation of global OTC drugs market by route of administration 2015
  • Exhibit 28: Global OTC drugs market by geography 2015-2020
  • Exhibit 29: Percentage share of global OTC drugs market by geography 2015 and 2020
  • Exhibit 30: Global OTC drugs market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 31: Global share of OTC drugs market by geography 2015
  • Exhibit 32: Global OTC drugs market: Country analysis based on revenue and growth rate
  • Exhibit 33: OTC drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 34: Major attributes of OTC medicines
  • Exhibit 35: OTC drugs market in US 2015-2020 ($ billions)
  • Exhibit 36: OTC drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 37: OTC market in EMEA: Short term versus long term 2015-2017
  • Exhibit 38: Distribution channels of key countries in Europe
  • Exhibit 39: Percentage share of Europe and MEA in OTC drugs market in EMEA 2015
  • Exhibit 40: Snapshot of OTC market in Germany
  • Exhibit 41: Distribution system of OTC drugs market in Germany
  • Exhibit 42: YoY OTC drug revenues from distribution chains in Germany 2014-2015 ($ millions)
  • Exhibit 43: OTC drugs market in Germany 2015-2020 ($ billions)
  • Exhibit 44: Key takeaways from market dynamics of European countries 2015-2017
  • Exhibit 45: OTC drugs market in France 2015-2020 ($ billions)
  • Exhibit 46: OTC drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 47: OTC drugs market in China 2015-2020 ($ billions)
  • Exhibit 48: OTC drugs market in Japan 2015-2020 ($ billions)
  • Exhibit 49: Growth factors of OTC market in India
  • Exhibit 50: OTC drugs market in India 2015-2020 ($ billions)
  • Exhibit 51: Factors promoting and inhibiting switch of Rx to OTC
  • Exhibit 52: Rx to OTC switch in US 2011-2015
  • Exhibit 53: Potential future candidates for OTC medications
  • Exhibit 54: Saving made by swapping branded for non-prescription generics for few drugs
  • Exhibit 55: Impact of drivers
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Promotional activities during various stages of OTC product lifecycle
  • Exhibit 58: Presence of vendors in different therapy areas in OTC drugs market
  • Exhibit 59: Geographical presence of key vendors in OTC drugs market 2015
  • Exhibit 60: Competitive scenario of global OTC drugs market vendors 2015-2020
  • Exhibit 61: Market share of key vendors based on revenue 2015
  • Exhibit 62: GSK: Product category (consumer healthcare) by revenue 2013-2015
  • Exhibit 63: GSK: YoY revenue and growth rate of wellness products 2013-2015 ($ billions)
  • Exhibit 64: GSK: YoY revenue and growth rate of skin health products 2013-2015 ($ millions)
  • Exhibit 65: GSK: Geographical segmentation by revenue (consumer health) 2015
  • Exhibit 66: GSK: Metrics analysis
  • Exhibit 67: Johnson & Johnson: Product category (consumer healthcare) by revenue 2014
  • Exhibit 68: Johnson & Johnson: Revenue and growth rate of OTC products 2013-2015 ($ billions)
  • Exhibit 69: Johnson & Johnson: Geographical segmentation by revenue (consumer healthcare) 2015
  • Exhibit 70: Johnson & Johnson: Metrics analysis
  • Exhibit 71: Pfizer: YoY revenue and growth rate of OTC drugs 2013-2015 ($ billions)
  • Exhibit 72: Pfizer: Metrics analysis
  • Exhibit 73: Bayer HealthCare: Consumer health segmentation by revenue 2015
  • Exhibit 74: Bayer HealthCare: Geographic segmentation of consumer healthcare segment 2015
  • Exhibit 75: Bayer HealthCare: YoY revenue and growth rate of Aspirin 2013-2015 ($ millions)
  • Exhibit 76: Bayer HealthCare: YoY revenue and growth rate of Aleve 2013-2015 ($ millions)
  • Exhibit 77: Bayer HealthCare: YoY revenue and growth rate of Bepanthen/Bepanthol 2013-2015 ($ millions)
  • Exhibit 78: Bayer HealthCare: YoY revenue and growth rate of Canesten 2013-2015 ($ millions)
  • Exhibit 79: Bayer HealthCare: Metrics analysis
  • Exhibit 80: Sanofi: Geographical segmentation by revenue 2015 (consumer healthcare)
  • Exhibit 81: Sanofi: YoY revenue and growth rate of Allegra 2013-2015 ($ millions)
  • Exhibit 82: Sanofi: YoY revenue and growth rate of Doliprane 2013-2015 ($ millions)
  • Exhibit 83: Sanofi: YoY revenue and growth rate of Essentiale 2012-2014 ($ million)
  • Exhibit 84: Sanofi: YoY revenue and growth rate of Enterogermina 2013-2015 ($ millions)
  • Exhibit 85: Sanofi: YoY revenue comparison of Nasacort 2014-2015 ($ millions)
  • Exhibit 86: Sanofi: YoY revenue and growth rate of Buscopan 2013-2015 ($ millions)
  • Exhibit 87: Sanofi: YoY revenue and growth rate of Dulcolax 2013-2015 ($ millions)
  • Exhibit 88: Sanofi: YoY revenue and growth rate of Mucosolvan 2013-2015 ($ millions)
  • Exhibit 89: Sanofi: YoY revenue and growth rate of Pharmaton 2013-2015 ($ millions)
  • Exhibit 90: Sanofi: Metrics analysis
Back to Top